NCT00379561

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

A Phase 1 Trial of PSA-Activated PSA-PAH1 Therapy for Locally Recurrent Prostate Cancer Without Metastases After Primary Radiation Therapy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Sophiris Bio Corp · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This Phase 1 trial will evaluate the safety and tolerability of PSA-Activated PSA-PAH1 in subjects who have shown biochemical failure and have either completed at least one primary radiation therapy for prostate cancer and have evidence of recurrent local prostate cancer without metastases.

Detailed description

For more information please contact Primary Investigator or Protox Therapeutics, Inc.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	PSA-Activated PSA-PAH1

Timeline

• Start date: 2006-03-01
• Primary completion: 2007-05-01
• Completion: 2008-07-01
• First posted: 2006-09-22
• Last updated: 2018-10-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study